Abstract:AIM:To express the HSP65-MUC1 VNTR(2) in E.coli and to evaluate its activity of inhibiting tumor growth in vivo.METHODS:HSP65 and MUC1 VNTR(2) were generated by PCR method and sub-cloned to pET28a(+) to construct the recombinant expression vector HSP65-MUC1 VNTR(2)-pET28a(+). E.coli BL21(DE3) bearing the plasmid was induced with IPTG for protein production. Target protein was characterized by Western blot with monoclonal antibody and purified by Q-Sepharose ion-exchange chromatography and gel filtration. The murine cancer cell linejB16 that transfected by human gene MUC1 was utilized to construct the model of carcinoma, and the tumor growth inhibition activities of HSP65-MUC1VNTR(2) was evaluated in mice C57BL/6.RESULTS:The gene HSP65 and MUC1 VNTR(2) confirmed by sequence analysis matched respectively with BCG HSP65 and human gene MUC1 VNTRs in GenBank exactly. The reconstructed vector HSP65-MUC1 VNTR(2)-pET28a could express target protein stably in the soluble fraction of bacterial extract. The purity of HSP65-MUC1 VNTR(2) protein could be above 95% after purification by Q ion-exchange chromatography and gel filtration. The result of Western blot with monoclonal antibody showed positive. The results of prophylactic immunization with HSP65-MUC1 VNTR(2) fusion protein showed that experiment all groups had significantly higher tumor inhibition rates than that of control group.CONCLUSION:In summary, HSP65-MUC1 VNTR(2) fusion protein was solubly expressed in prokaryotic expression system and its tumor growth inhibition activity was evaluated primarily. The result indicated that the fusion protein could inhibit the MUC1 positive tumor growth significantly. It can be used in the future research as the cancer vaccine.

Purification of clinical-grade recombinant HSP65-MUCI fusion protein.

Pre-Clinical Safety Evaluation Of Heat Shock Protein 65-Muc1 Peptide Fusion Protein

Purification of a Non-Tagged Recombinant BCG Heat Shock Protein 65-Her2 Peptide Fusion Protein from Escherichia Coli.

The Basic Study and Purification Strategy of MAGE-1/MAGE-3/Heat Shock Protein 70 Fusion Protein Tumor Vaccine

Prokaryotic Expression, Purification of HSP65-MUC1 VNTR2 Fusion Protein and Primary Research on Its Tumoricidal Effect

Purification and Stability Research of Mycobacterial Heat Shock Protein 65 and Its Fusion Protein Hsp65-6 P277

Expression and Purification of the Fusion Protein Comprising Mycobacterium Tuberculosis Heat Shock Protein 65 and Human Interleukin 2

Prokaryotic expression and purification of 8R-MUC1 core peptide fusion protein

Heat Shock Fusion Protein Induces Both Specific And Nonspecific Anti-Tumor Immunity

Refolding and two-step purification by hydrophobic interaction chromatography of recombinant human bone morphogenetic protein-2 from Escherichia coli

Purification Of Recombinant Gm-Csf/Il-3 Fusion Protein

Expression,purification and identification of Hsp-65 protein from Mycobacterium tuberculosis

Expression and Purification of Secreted Recombinant Hsp60 from Eukaryotic Cells

Gene Recombinant and Prokaryotic Expression of HSP65-T Cell Epitopes of MOMP of C. Trachomatis Fusion Protein and Its Purification

Expression and identification of recombinant human IL-2 and MUCI fusion protein in E.coli BL21

Expression and Purification of the HPV16E7-HSP70 Fusion Protein in Escherichia coli

Purification and Identification of Recombinant Human Granulocyte Colony-Stimulating Factor Muteint (Rhg-Csf-ala-17)

High-Level Expression and Purification of Human Epidermal Growth Factor with SUMO Fusion in Escherichia Coli

An Efficient Scheme for Purification of a Novel Recombinant Immunotoxin, Rcck8pe38, for Anti-Tumour Experiments.

The Expression and Purification of HSP65 Antigen from Mycobacterium Tuberculosis in E.Coli

Construction,expression and purification of a fusion gene of MAGE-n peptide with human heat shock protein 70